Paragon Care Ltd

Healthcare AU PGC

0.47AUD
0.01(2.17%)

Last update at 2024-11-13T05:10:00Z

Day Range

0.460.47
LowHigh

52 Week Range

0.170.50
LowHigh

Fundamentals

  • Previous Close 0.46
  • Market Cap794.55M
  • Volume228838
  • P/E Ratio48.00
  • Dividend Yield-%
  • EBITDA25.78M
  • Revenue TTM317.02M
  • Revenue Per Share TTM0.48
  • Gross Profit TTM 125.53M
  • Diluted EPS TTM0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax 20.85M 10.69M 12.33M -77.20300M 12.19M
Minority interest -2.80400M -0.51000M - - -
Net income 10.76M 6.63M 8.28M -77.26900M 8.77M
Selling general administrative 70.09M 60.12M 50.71M 53.52M 61.51M
Selling and marketing expenses 11.21M 8.70M 7.24M 5.21M 7.13M
Gross profit 126.32M 102.83M 90.31M 86.81M 95.10M
Reconciled depreciation 10.29M 7.98M 6.20M 8.05M 10.01M
Ebit 27.56M 20.99M 19.51M -4.57300M 18.15M
Ebitda 37.86M 28.97M 25.71M 3.48M 28.16M
Depreciation and amortization 10.29M 7.98M 6.20M 8.05M 10.01M
Non operating income net other - - - - -
Operating income 23.26M 13.29M 13.98M -1.43000M 18.15M
Other operating expenses 83.31M 59.53M 74.01M 3.71M 219.68M
Interest expense 5.93M 5.70M 7.17M 5.61M 5.96M
Tax provision 5.20M 3.54M 4.05M -5.60300M 3.45M
Interest income 0.38M 0.13M 0.02M 7.06M 5.95M
Net interest income -6.64000M -5.97900M -7.99400M -5.60900M -5.38400M
Extraordinary items -2.08900M - 0.00000M -5.66900M -23.24800M
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.20M 3.54M 4.05M -5.60300M 3.42M
Total revenue 307.63M 247.91M 235.84M 231.69M 236.09M
Total operating expenses 102.22M 84.12M 72.86M 84.75M 78.69M
Cost of revenue 181.31M 145.08M 145.53M 144.87M 140.99M
Total other income expense net 3.39M -2.04700M 2.87M -72.39800M -5.95900M
Discontinued operations -2.08900M 0.34M 0.34M -5.66900M -23.24800M
Net income from continuing ops 15.65M 7.14M 8.28M -71.60000M 8.77M
Net income applicable to common shares 10.76M 6.63M 8.28M -77.26900M -14.38600M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 1130.89M 448.52M 437.03M 291.92M 292.17M
Intangible assets - 6.73M 3.36M 2.37M 0.66M
Earning assets - - - - -
Other current assets 3.26M 1.73M 9.20M 0.13M 3.56M
Total liab 838.97M 196.56M 194.69M 170.40M 179.89M
Total stockholder equity 291.92M 242.85M 236.03M 121.52M 112.28M
Deferred long term liab - - - - -
Other current liab 22.55M 29.03M 27.52M 25.55M 41.78M
Common stock 328.49M 232.30M 228.66M 113.95M 202.72M
Capital stock - 232.30M 228.66M 113.95M 202.72M
Retained earnings -36.24500M 10.10M 7.53M 8.28M -88.76600M
Other liab - 2.59M 2.26M 0.62M 0.47M
Good will - 252.33M 241.02M 149.00M 149.00M
Other assets 0.00000M 9.72M 11.31M 10.84M 14.76M
Cash 19.94M 22.60M 46.20M 33.20M 24.50M
Cash and equivalents - - - - -
Total current liabilities 701.92M 93.55M 87.38M 82.21M 84.88M
Current deferred revenue 9.48M 6.16M 10.10M 1.00M 1.71M
Net debt 231.88M 99.54M 85.06M 79.81M 90.52M
Short term debt 116.75M 21.72M 26.21M 25.44M 20.49M
Short long term debt - 17.09M 22.69M 21.59M 15.95M
Short long term debt total 251.83M 122.14M 131.26M 113.01M 115.03M
Other stockholder equity -0.32500M -242.39900M -236.18400M -122.23100M -113.95200M
Property plant equipment - 44.92M 30.50M 16.50M 21.45M
Total current assets 681.52M 132.65M 150.84M 113.21M 106.31M
Long term investments - 2.17M 0.26M - -
Net tangible assets - -16.21500M -8.34900M -29.85600M -37.37900M
Short term investments - - - - 0.00000M
Net receivables 350.58M 39.43M 42.92M 26.20M 31.57M
Long term debt - 67.60M 73.40M 80.40M 81.90M
Inventory 307.74M 63.69M 51.45M 51.58M 46.66M
Accounts payable 553.13M 36.65M 23.56M 30.22M 20.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 10.55M 7.38M 7.57M -1.67100M
Additional paid in capital - - - - -
Common stock total equity - - - - 202.72M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.08M - - -167.87000M -171.10900M
Deferred long term asset charges - - - - -
Non current assets total 449.37M 315.87M 286.19M 178.71M 185.87M
Capital lease obligations - 37.45M 35.18M 11.03M 17.18M
Long term debt total - 100.42M 105.05M 87.57M 94.54M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -19.52500M -31.74600M 7.07M -18.80300M 0.02M
Change to liabilities - 3.68M -14.95700M 13.71M -27.44400M
Total cashflows from investing activities - -31.74600M 7.07M -18.80300M -11.40300M
Net borrowings - -15.71900M -11.44700M 0.03M -3.60300M
Total cash from financing activities -13.87300M -10.00200M -11.93000M 0.03M -3.60300M
Change to operating activities - -1.06500M -4.58700M -1.51600M 4.75M
Net income 8.38M 10.76M 6.09M 8.28M -71.60000M
Change in cash -2.65900M -23.60000M 13.01M 8.69M -9.71900M
Begin period cash flow 22.60M 46.20M 33.20M 24.50M 34.22M
End period cash flow 19.94M 22.60M 46.20M 33.20M 24.50M
Total cash from operating activities 53.90M 17.75M 19.03M 27.46M 5.29M
Issuance of capital stock - 0.42M 0.48M - -
Depreciation 14.47M 8.86M 7.94M 6.20M 8.05M
Other cashflows from investing activities - -10.70000M 11.68M -0.13400M 0.07M
Dividends paid 12.61M 7.89M 0.00104M 7.89M 7.89M
Change to inventory -12.75600M -12.43100M 8.29M -4.91600M 4.75M
Change to account receivables -99.08800M -1.10100M 7.72M 5.87M 17.09M
Sale purchase of stock - -0.01900M -0.01900M - 0.00000M
Other cashflows from financing activities -7.98100M 7.46M -3.52800M 3.37M -3.45200M
Change to netincome - 3.25M 7.32M -0.16300M 75.37M
Capital expenditures 20.82M 21.05M 4.61M 5.29M 7.27M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 27.76M -13.53200M -5.15600M 9.23M 6.50M
Stock based compensation - 0.35M 0.85M 0.07M -14.35300M
Other non cash items 12.59M -1.87200M 7.14M -0.23200M 84.05M
Free cash flow 33.08M -3.29700M 14.42M 22.18M -1.97900M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PGC
Paragon Care Ltd
0.01 2.17% 0.47 48.00 5.98 2.51 2.38 0.31 21.47
EBO
EBOS Group Ltd
-0.18 0.53% 34.02 23.78 26.67 0.49 2.66 0.60 13.19
SIG
Sigma Pharmaceuticals Ltd
- -% 2.50 - 69.44 1.07 3.51 0.84 68.68

Reports Covered

Stock Research & News

Profile

Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health, aged care, and veterinary markets in Australia, New Zealand, and Asia. It operates through four segments: Diagnostic and Scientific, Devices, Capital and Consumables, and Service and Technology. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, biologics, and the operating room; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care diagnostics, therapeutic lasers, oncology delivery products, centrifuges, autoclaves, IV lines and fluid therapy products, wearable CRI systems, and IT Solutions. Further, it provides digital theatre integration, telephony, nurse call, access control, CCTV, cordless, and Wi-Fi systems; and anaesthesia masks, circuits, filters, bladder scanners, and defibrillators. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. The company was incorporated in 1994 and is based in Mt Waverley, Australia.

Paragon Care Ltd

77-97 Ricketts Road, Mt Waverley, VIC, Australia, 3149

Key Executives

Name Title Year Born
Mr. Mark Robert Hooper BBus (Acc), C.P.A., CPA, FFTP, M.A.I.C.D., MAICD Group CEO, MD & Director 1959
Mr. Stephen J. Munday Exec. Officer 1964
Mr. John Andrew Walstab Exec. Director & Exec. GM of Paragon Care Asia 1963
Ms. Josephine De Martino Chief Financial Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Joint Company Sec. 1973
Ms. Claire Newstead-Sinclair BBus, C.A., CA Joint Company Sec. NA
Mr. Michael G. Rice Group Commercial Mang. 1976
Mr. John Andrew Walstab Group CEO, MD & Executive Director 1963
Ms. Melanie Jaye Leydin B.Bus, C.A. Joint Company Secretary 1973
Ms. Claire Newstead-Sinclair BBus, C.A., CA Joint Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.